INNSBRUCK, Austria, September 1, 2014 /PRNewswire/ --

Austrian BIOCRATES Life Sciences AG, internationally renowned developer and marketer of innovative targeted metabolomics solutions, further expands its range of metabolomics-based kits with the addition of its assay for the determination of endogenous bile acids, allowing a panel of up to 19 analytes to be simultaneously quantitated from a single 10 µL sample of human or mouse plasma. 

BIOCRATES Life Sciences AG, developer of cutting-edge mass-spectrometry-based kit products, announces the launch of the first-ever bile acids kit based on targeted metabolite quantitation.
Bile acids are essential for regulating cholesterol metabolism and the intestinal digestion and absorption of fat. Their signaling functions play an important role in chronic disorders, sepsis, or drug metabolism. BIOCRATES Life Sciences has now developed an assay for the standardized analysis of 16 human specific and 19 mouse specific bile acids from sample sizes as small as 10 µL designed for research use. The BIOCRATES^® Bile Acids Kit* is based on (ultra) high performance liquid chromatography coupled with electrospray tandem mass spectrometry (UHPLC-MS/MS) and is characterized by quick and highly effective sample extraction on a 96-well patented filter plate. To ensure accuracy and precision, the kit comes with a set of calibration standards, isotope-labeled internal standards, and quality control samples. The assay has been rigorously validated to European Medicines Agency (EMA) guidelines.

*For research use only (RUO)

About BIOCRATES 

BIOCRATES Life Sciences AG offers unique solutions for targeted, standardized and quality-controlled metabolic phenotyping. The company's mass spectrometry-based assays are marked by unprecedented accuracy and precision, providing a comprehensive understanding of phenotypes and metabolic pathways.  

For more information, please go to http://www.biocrates.com.

BIOCRATES Life Sciences AG
Martina Klocker
Martina.Klocker@biocrates.com
Phone: +43-(0)-512-579823

SOURCE BIOCRATES Life Sciences AG